Millennium Group discloses 8.4% BioXcel Therapeutics (BTAI) ownership in 13G/A
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. has an updated ownership disclosure as several Millennium-affiliated entities and Israel A. Englander filed an amended Schedule 13G reporting significant holdings of the company’s common stock. Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report beneficial ownership of 1,835,192 shares, representing 8.4% of the common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,833,717 shares, also representing 8.4% of the class. The filers state the securities are not held for the purpose of changing or influencing control of BioXcel Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Schedule 13G/A filing disclose about BioXcel Therapeutics (BTAI)?
The filing discloses that Millennium-affiliated entities and Israel A. Englander beneficially own a significant stake in BioXcel Therapeutics common stock. They report holdings of roughly 8.4% of the outstanding shares and certify the investment is not for changing or influencing control of the company.
What is Integrated Core Strategies (US) LLC’s ownership in BioXcel Therapeutics (BTAI)?
Integrated Core Strategies (US) LLC reports beneficial ownership of 1,833,717 shares of BioXcel Therapeutics common stock. This stake represents 8.4% of the company’s common stock class, with shared voting and dispositive power over all of these reported shares.
Who are the reporting persons in this BioXcel Therapeutics (BTAI) Schedule 13G/A?
The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. All Millennium entities are organized in Delaware, while Mr. Englander is a United States citizen, according to the ownership disclosure.
Do the Millennium entities seek to influence control of BioXcel Therapeutics (BTAI)?
The reporting persons certify that their BioXcel Therapeutics shares were not acquired and are not held for the purpose of changing or influencing control. They also state the holdings are not part of any transaction designed to affect control, aside from activities tied to certain nomination rules.
What key dates are associated with this BioXcel Therapeutics (BTAI) ownership filing?
The date of the event triggering the Schedule 13G/A filing is listed as December 31, 2025. The joint filing agreement and signatures, including those by Gil Raviv and Israel A. Englander, are dated February 6, 2026 in the ownership disclosure.